KETEK
LOE ApproachingNDAORALTABLET
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
KETEK by Sanofi is clinical pharmacology pharmacokinetics absorption following oral administration, telithromycin reached maximal concentration at about 1 hour (0. Approved for community-acquired pneumonia (of mild to moderate severity) due to streptococcus pneumoniae, (including multi-drug resistant isolates [mdrsp mdrsp, multi-drug resistant streptococcus pneumoniae includes isolates known and 2 more indications. First approved in 2004.
Drug data last refreshed 3d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Following oral administration, telithromycin reached maximal concentration at about 1 hour (0.5 – 4 hours). It has an absolute bioavailability of 57% in both young and elderly subjects. The rate and extent of absorption are unaffected by food…
Worked on KETEK at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.